<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "mannitol inj BAG">
<dose><value></value>
<value>250</value>
</dose><route><value>IV</value>
</route><form><value>inj BAG</value>
</form><drugname><value>mannitol inj BAG</value>
</drugname><strength><value>100 mg/mL</value>
<value>200 mg/mL</value>
</strength><frequency><value>CONTINUOUS</value>
<value>ONCE</value>
</frequency><instruction><value>Administer by continuous infusion.</value>
<value>DAY 1. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 8. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 1 of 21. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 1 of 28. Administer over one hour concurrently with CISplatin.</value>
<value>DAY 8 of 28. Administer over one hour concurrently with CISplatin.</value>
</instruction><volume><value>1000 mL</value>
<value>500 mL</value>
</volume><units><value>mL/hr</value>
<value>mL</value>
</units><additionalnotes><value></value>
</additionalnotes><population><value></value>
<value>Adjuvant Vinorelbine/CISplatin (every 28 days). Non-Small Cell Lung Cancer</value>
<value>Adjuvant Vinorelbine/CISplatin (every 21 days). Non-Small Cell Lung Cancer</value>
<value>Pemetrexed/CISplatin. Non-Small Cell Lung Cancer</value>
<value>Vinorelbine / CISplatin. Advanced NSCLC</value>
<value>CISplatin &amp; Vinorelbine with CONCURRENT RT. Non-Small Cell Lung Cancer</value>
<value>Gemcitabine / CISplatin. Non-Small Cell Lung Cancer</value>
<value>CISplatin/etoposide (po). Small Cell Lung Cancer</value>
<value>Pemetrexed / CISplatin. Mesothelioma.</value>
<value>Etoposide (Days 1-5)/CISplatin (Days 1 &amp; 8) with concurrent RT. Pancoast Tumor</value>
<value>DOXOrubicin/CISplatin/cyclophosphamide (PAC). Thymic Malignancy</value>
<value>CISplatin/DOXOrubicin/vinCRIStine/cyclophosphamide. Thymoma</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value></value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
<value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Kidney Function</value>
</ahfsname><highalert><value></value>
</highalert><maximumprndose><value></value>
</maximumprndose></drug>